Solid forms of an antiviral compound
First Claim
1. Crystalline (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid D-tartrate (Compound I D-tartrate), characterized by an X-ray powder diffractogram comprising the following peaks:
- 4.0, 10.3, and 19.7 °
2θ
±
0.2 °
2θ
, as determined on a diffractometer using Cu-Kα
radiation at a wavelength of 1.54178 Å
.
3 Assignments
0 Petitions
Accused Products
Abstract
Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state:
Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
-
Citations
5 Claims
-
1. Crystalline (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid D-tartrate (Compound I D-tartrate), characterized by an X-ray powder diffractogram comprising the following peaks:
- 4.0, 10.3, and 19.7 °
2θ
±
0.2 °
2θ
, as determined on a diffractometer using Cu-Kα
radiation at a wavelength of 1.54178 Å
. - View Dependent Claims (2, 3, 4, 5)
- 4.0, 10.3, and 19.7 °
Specification